Clinical trials: FLU
Influenza
H5N1 Priming and Boosting Strategies
Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu.
- Trial name
- NCT00703053
- Testing
- A/Vietnam/1203/04, A/Indonesia/05/05
- Where
- 5 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Influenza
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
The goal of this study is to understand the impact on the human immune system's response to the four strain flu vaccine in individuals who have "imprinted" on specific influenza strains.
- Trial name
- FLU2 (NCT03686514)
- Testing
- FLUARIX QUADRIVALENT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Influenza
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT03969212
- Testing
- Baloxavir Marboxil
- Where
- 142 sites in United States, Bulgaria and 14 more
- Volunteers
- 4,138 people
- Sponsor
- Hoffmann-La Roche
Influenza
Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)
The primary purpose of the study is to assess the equivalence of the immune response elicited by two GSK Biologicals' adjuvanted influenza investigational vaccines (GSK2340272A and GSK2340274A) in adults aged 18 to 60 years.
- Trial name
- NCT00979407
- Testing
- Influenza vaccine GSK2340272A, Influenza vaccine GSK2340274A
- Where
- 7 sites in France, Germany
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine
In this Phase II randomized controlled clinical trial, generally healthy male and female children from 24 through 59 months of age will be enrolled in Kamalapur (Dhaka), Bangladesh.
- Trial name
- NCT01625689
- Testing
- SIIL LAIV (live, trivalent seasonal influenza vaccine)
- Where
- Bangladesh
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- PATH Vaccine Solutions
Flu Vaccine
Senescent Immunity in Elders and Vaccine Responses (SILVER)
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
- Trial name
- NCT04077424
- Testing
- Fluzone-High Dose Quadrivalent, Fluad, Flublock
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2010/2011 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01306305
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine
The study hypothesis is that two 0.5 ml doses of non-adjuvanted whole virion monovalent A/H1N1 influenza vaccine (IVACFLU)--each dose with an HA content of 15 mcg from A/California/07/2009 (H1N1)-like virus--will be safe and…
- Trial name
- NCT01507779
- Testing
- IVACFLU
- Where
- Vietnam
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza Vaccine
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50…
- Trial name
- NCT04785794
- Testing
- Sing2016 M2SR H3N2 influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important…
- Trial name
- NCT03028987
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
The present study aims to evaluate safety, tolerability and immunogenicity of three lots of Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine…
- Trial name
- NCT00310804
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
- Where
- 2 sites in Lithuania
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine
This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or placebo (phosphate buffered…
- Trial name
- NCT02585700
- Testing
- Influenza vaccine, split inactivated
- Where
- Serbia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute of Virology, Vaccines and Sera, Torlak
Influenza
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to < 18 years of age who are at risk of complications of influenza disease due to underlying diseases.
- Trial name
- NCT01998477
- Testing
- TIVc, TIV
- Where
- 16 sites in Italy, Spain
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infectious Diseases, Influenza
Development of Immune Globulin Treatment for Avian Flu
This study will determine how best to use a vaccine for generating high levels of antibodies called immune globulins (IVIG) in people, which, in turn, can be collected and used to develop a possible treatment for avian influenza…
- Conditions
- Infectious Diseases, Influenza, Avian Flu
- Trial name
- NCT00383071
- Testing
- H5N1 vaccine, Apheresis
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
The purpose of this study is to evaluate the safety of a single intramuscular (IM) injection of the cell derived subunit trivalent nonadjuvanted influenza vaccine in adult and elderly subjects and the antibody response to each…
- Trial name
- NCT01640314
- Testing
- Cell derived subunit trivalent nonadjuvanted vaccine
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent…
- Trial name
- NCT01579916
- Testing
- Trivalent Influenza Virus Vaccine
- Where
- 3 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC